Anticancer

Alizarin
Catalog No: CFN92568

Alizarin has a selective and effective inhibitory activity towards cancerous cells, it acts through the inhibition of ERK phosphorylation and cell cycle arrest in the S-phase. Alizarin has antigenotoxic activity, which can be explained by inhibition of CYP activities responsible for activating the mutagens.

Periplocin
Catalog No: CFN90513

Periplocin has anti-cancer, and potent immunoregulatory effects, it induces apoptosis and inhibits growth of cancer cells by the beta-catenin/Tcf signaling pathway. Periplocin is used for treatment of rheumatoid arthritis, reinforcement of bones and tendons, palpitations or shortness of breath and lower extremity edema in traditional medicine.

Amarogentin
Catalog No: CFN90519

Amarogentin incorporated in liposomes or niosomes may have clinical application in the treatment of leishmaniasis. It plays cemopreventive/therapeutic role during liver carcinogenesis through modulation of cell cycle and apoptosis. Amarogentin may offer therapeutic potential for preventing or treating thromboembolic disorders, it prevents platelet activation through the inhibition of PLC γ2-PKC cascade and MAPK pathway.

Demethylwedelolactone
Catalog No: CFN90521

Demethylwedelolactone has trypsin inhibitory effect, it exerts anti-invasive growth effect on breast cancer cells.

Acetylshikonin
Catalog No: CFN90523

Acetylshikonin has anti-cancer and anti-inflammatory activity, it is a novel general P450 inhibitor with IC50 values of 1.4-4.0 μM for all tested P450s. Acetylshikonin exhibits weak cytotoxicity against human umbilical vein endothelial cells (HUVECs) with IC50 of over 20 microM, exhibits the antiangiogenic and antitumorigenic effects by suppressing proliferation and angiogenic factors. Certain shikonin derivatives(such as Acetylshikonin) act as modulators of the Nur77-mediated apoptotic pathway.